Testing a combination therapy for hemophagocytic lymphohistiocytosis
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial tests a new combination of medicines (the GO regimen) for people with hemophagocytic lymphohistiocytosis (HLH) that is either newly diagnosed, has come back, or hasn't responded to other treatments. It aims to see if this approach can help when a stem cell transplant isn't an option right now.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have HLH that is newly diagnosed, has come back, or hasn't responded to treatment.
- Your doctor has confirmed HLH using standard diagnostic criteria or genetic testing.
- You are not able to have a stem cell transplant at this time.
- You are between 14 and 70 years old.
- Your heart, liver, kidney, and certain infection tests meet basic safety levels.
- You are willing to use effective birth control during and for a time after the study if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of five drugs to treat a rare blood cancer called NK/T-cell lymphoma that has triggered an abnormal immune response (hemophagocytic lymphohistiocytosis). The goal is to control both the cancer and the harmful immune reaction.
This trial tests a new drug called golidocitinib added to standard chemotherapy (CHOP) for people newly diagnosed with certain types of T-cell lymphoma. It aims to see if the combination works better than CHOP alone.
This trial tests a combination of two drugs, emapalumab and ruxolitinib, for people with hemophagocytic lymphohistiocytosis (HLH), a rare condition where the immune system becomes overactive and damages organs. The goal is to control the disease with fewer side effects than standard treatments.
This trial tests a combination of a targeted drug (ruxolitinib) with a less intense version of standard chemo for adults with Hemophagocytic Lymphohistiocytosis (HLH). It aims to control the overactive immune response while reducing side effects.
This study is testing a modified treatment regimen (called DEP) with or without the drug ruxolitinib for patients with HLH, a serious condition where the immune system attacks the body. The goal is to see if this combination is safe and helps control the disease.
This trial looks at how people with lymphoma-related hemophagocytic lymphohistiocytosis (HLH) respond to treatment. It aims to better describe expected outcomes and who benefits most, which may help guide future care.
Hear when a new Lymphohistiocytosis, Hemophagocytic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.